Abstract: A combination emergency wash and faucet unit includes a base, an emergency wash arm pivotally coupled to the base, and a spout pivotally coupled to the base. The emergency wash arm includes an emergency wash unit that is rotatable relative to the base about a first vertical axis. The spout is rotatable relative to the base about a second vertical axis. The first vertical axis is offset from the second vertical axis.

Abstract: A somatosensation and proprioceptor stimulation surface configured to stimulate rapid-firing nerves in the receptive field of a user's glabrous skin. The somatorsensation and proprioceptor stimulation surface includes a plurality of protuberances disposed thereupon, each protuberance sized and spaced apart appropriately to impress the receptive field when pressed in contact with the glabrous skin of the user. Each protuberance widens from an apex toward a base whereby increased pressure applied to the surface increases an area of contact and stimulation by applying stimulation over a larger area of skin. The protuberances are spaced apart to maximize stimulation of rapid firing nerves while lessening overstimulation. The somatosensation and proprioceptor stimulation surface is rendered in the form of a mat or floor covering and alternatively as an insole for wear in a user's shoes.

Abstract: A sealed pharmaceutical container includes a shoulder, a neck extending from the shoulder, and a flange extending from the neck. The flange includes an inclined sealing surface defining an opening in the sealed pharmaceutical container. The sealed pharmaceutical container also includes a sealing assembly including a stopper extending over the sealing surface of the flange and a cap securing the stopper to the flange. The stopper has a glass transition temperature (Tg) that is greater than or equal to ?70° C. and less than or equal to ?45° C. The sealing assembly maintains a helium leakage rate of the sealed pharmaceutical container of less than or equal to 1.4×10?6 cm3/s as the sealed pharmaceutical container is cooled to a temperature of less than or equal to ?45° C.

Abstract: A medical device including an application device with a first fluid path and a container movably attached to the application device. The container and the application device have a second fluid path therethrough, the container includes an inner chamber that is intermediate proximal and distal portions of the second fluid path, the inner chamber is fluidly isolated from the proximal portion of the second fluid path at a first position of the container, and the inner chamber is fluidly coupled to the proximal and distal portions of the second fluid path at a second position of the container. The first fluid path bypasses the container and the passage of fluid through the first fluid path is separately controllable from the passage of fluid through the second fluid path.

Abstract: A male-female adapter (21) can be coupled to a hermetically closable connector (1) with external threading (13) and closing plug (6) which can be bored by pressure of a male fitting so as to form a connector (1)—adapter (21) unit which is suitable for using a female fitting. The adapter (21) comprises an external tubular body (22) with an axial extension (24) which can be hooked to the connector (1) in a rotatable and axially slidable manner, an internal tubular body (26) with terminal tangs (27, 37) axially projecting from the extremities of the external tubular body (22), a middle transversal wall (28) which integrally connects the two tubular bodies (22, 26), and two opposite sense threadings (29, 30) formed in internal portions of the external tubular body (22), which threadings are separated by said middle transversal wall (28).

Abstract: A method for filling a reservoir a filling assembly having a needle, and a fluid. The reservoir is in a disposable housing assembly with a septum fluidly connected to the reservoir, a septum access assembly having a first position covering the septum and a second position providing access to the septum, and a bias mechanism for biasing the septum access assembly to the first position. The method includes piercing the septum with the needle, inserting fluid to the reservoir through the needle, contacting the filling assembly to the septum access assembly, and removing the needle from the septum. Removing the needle from the septum allows the bias mechanism to move the septum access assembly from the second position to the first position. The disposable housing assembly is attached to a reusable housing assembly.

Abstract: A carousel configured to house a plurality of pump cartridges for a compounder system is provided. The carousel may include a plurality of cartridge pockets each having an extended portion that covers a portion of a cartridge and a bottom surface Shaving an extension with a recess. The bottom surface recess of each cartridge pocket may be shaped and sized to receive a needle housing of a pump cartridge in the cartridge pocket. A recess may be provided in the extended portion of each pocket that receives a protrusion that extends from a top surface of a backpack coupled to the pump cartridge to secure the pump cartridge in the cartridge pocket. The bottom surface recess may have an additional bottom surface that prevents actuation of the needle housing of the pump cartridge.

Abstract: Dual vial adapter assemblages having a triple component construction as follows: a first vented female vial adapter for telescopic mounting on a drug vial, a second vented female vial adapter for telescopic mounting on a liquid vial and a tubular liquid transfer coupler for coupling the first vented female vial adapter and the second vented female vial adapter for establishing a dual sealed lumen arrangement therebetween. The dual sealed lumen arrangement includes a central sealed liquid lumen for gravitational flow of liquid contents from a liquid vial to a drug vial and a sealed air lumen radial outward from the central sealed liquid lumen for venting air displaced from the drug vial to the liquid vial for assisting the gravitational flow of liquid contents by creating a closed system between the liquid vial and the drug vial.

Abstract: A modular dispenser includes a cartridge configured to hold a plurality of pills. The cartridge includes an opening through which the at least one pill is configured to pass under an influence of gravity. A dispensing base is configured to removably receive the cartridge. The dispensing base includes a funnel with a funnel inlet proximate the opening of the cartridge and a funnel outlet spaced apart from the funnel inlet. A dispensing assembly is rotatably coupled to the dispensing base. The dispensing base also includes at least one catch configured to receive the at least one pill when the at least one catch is proximate the funnel outlet and to rotate the at least one catch away from the funnel outlet to a position from which the at least one pill is retrievable by a user.

Abstract: Pressed powder compositions are provided. The compositions include at least about 80% by weight of a mineral portion. The mineral portion comprises at least one alkylsilane-coated mineral; polyhydroxystearic acid, synthetic mica, and less than about 12% by weight of binding agents. Methods of shadowing the eyes and methods of forming pressed powder compositions are also provided.

Abstract: Provided is a liquid skin external composition which allows a poorly water-soluble component to be applied to a skin in a liquid state. An assembly of fiber for use in production of a liquid skin external composition, the assembly of fiber comprising (a) a polymer soluble in water and an alcohol or a ketone in a content of 50 mass % or more and 98 mass % or less with respect to the whole assembly of fiber and (b) a poorly water-soluble component in a content of 2 mass % or more and 40 mass % or less with respect to the whole assembly of fiber.

Abstract: The present invention relates generally to methods and compositions useful to cleanse, exfoliate, smooth, moisturize, hydrate, and/or improve the appearance and/or condition of skin and/or hair using a composition including shea butter, PEG-50 shea butter, and/or hydrated silica.

Abstract: Disclosed is a non-spherical microcapsule comprising a core comprising fatty ester having a melting point of at least 30° C. and a benefit agent; a shell comprising nanoparticles having a diameter of 10 to 300 nm.

Abstract: A method of treating a material, the method comprising contacting the material with a composition comprising a hydroxy-substituted aldehyde. In preferred aspects of the invention the material is a keratinous material.

Abstract: An aqueous cosmetic includes water, a polyhydric alcohol and carminic acid. A content of the carminic acid is greater than or equal to 0.2 mass % and less than 2 mass % based on a total amount of the aqueous cosmetic.

Abstract: A composition comprising at least two visually distinguishable phases, comprises at least one fatty phase with oil, at least one aqueous phase with hydrophilic gelling agent, and at least one compound chosen from N,N-dimethylglycine derivatives, alkyl(poly)glucosides, or a mixture thereof.

Abstract: An antimicrobial preservation system comprising: i. itaconic acid or salt thereof and ii. benzoic acid or salt thereof.

Abstract: Hair care compositions and methods for improving curl retention of hair are provided. The hair car composition may include a carrier and a quaternary ammonium compound. The method for improving curl retention may include contacting the hair care composition with surfaces of the hair of a subject in need thereof.

Abstract: Oral care compositions comprising an amino acid and stannous ion source, especially in the absence of zinc ion source, are provided for promoting Gum Health of a user.

Abstract: The present invention relates to a composition according to the present invention comprises: (a) at least one particle comprising at least one cationic polymer, at least one anionic polymer, and at least one hydrophilic or water-soluble UV filter; and (b) at least one physiologically acceptable volatile medium. The composition according to the present invention is stable, and can have a variety of cosmetic functions. For example, the composition according to the present invention can prepare a film which can have cosmetic effects such as UV filtering, as well as absorbing or adsorbing malodor, changing the appearance of a keratin substrate such as skin, changing the feel to the touch of the keratin substrate, and/or protecting the keratin substrate from, for example, dirt or pollutants.

Abstract: The present invention provides a composition that comprises at least one peptide with a sequence length of 6-12 amino acids, where 2-5 of those amino acids are cysteines for the treatment of the hair, including animal and human hair, without the use of chemicals harmful to the hair fiber and consumer health and uses of said compositions in shampoo, lotion, serum, cream, conditioner, foam, elixir, oil, aerosol or mask.

Abstract: Scleritine is used as a protective agent for cells against toxic agents, in particular chemical or physical agents. One or more embodiments relate to a dermatological and/or cosmetic composition, which protects the skin against toxic agents, characterized in that it comprises Scleritine in at least one excipient or vehicle adapted to a topical application. One or more embodiments concerns the pharmaceutical or cosmetic industry and more specifically the formulation of pharmaceutical or cosmetic compositions intended to protect cells against toxic agents.

Abstract: A method of selecting skin treatment regimens, ingredients and compositions that includes measuring the levels of particular small molecule metabolites on skin both before and after product application and testing for a change in small molecule metabolite levels is disclosed.

Abstract: The present disclosure relates to hair care systems comprising: (1) a booster composition containing at least one ionic polymer functionalized with at least one carboxylic acid moiety; optionally, at least one compound selected from an alkoxysilane, a nonionic latex polymer, or mixtures thereof; a thickening agent; and a cosmetically acceptable carrier; and (2) a hair treatment composition containing at least one surfactant selected from an anionic surfactant, an amphoteric surfactant, a cationic surfactant, a nonionic surfactant, or mixtures thereof. The hair care systems of the present disclosure can be used to clean and/or condition hair, as well impart frizz control and manageability benefits to hair.

Abstract: This cosmetic contains: (a) 30 mass % or less of a highly oil-absorbing powder; (b) a volatile oil solution; and (c) a nonvolatile oil solution having a kinematic viscosity at 25° C. of 5 to 100 mm2/s. The mixture mass ratio represented by (a)/(c) is 0.37 to 2.0.

Abstract: Disclosed are compositions for treating and conditioning keratinous substrates, comprising a cationic agent comprising quaternary ammonium compounds; a modified starch; silane compounds, a cationic vinylpyrrolidone polymer and water. Also disclosed are methods treating and conditioning keratinous substrates using the composition.

Abstract: Copolymers are formed of monomers of poly(dimethylsiloxane) and poly(alkylene oxide) of the following formula: Ax-XCH2CH2—[ByCz]n—X-Ax. In the formula, each X independently represents a —CH2— group or an oxygen atom, A represents a polydimethylsiloxane derivative, B represents a polyethylene glycol unit, C represents a polypropylene glycol unit, x and n independently represent an integer from 1 to 150, and y and z independently represent an integer from 0 to 150. The copolymers can be used as emulsifiers in personal care compositions.

Abstract: A composition for a skin and hair product enhances the overall look of hair.

Abstract: The present invention provides a fermented honey product obtained by fermenting a honey-containing material having a honey concentration of more than 25% with Lactobacillus kunkeei.

Abstract: Ambrisentan and formulations thereof for use in the treatment and prevention of acute renal failure associated with renal vasoconstriction.

Abstract: Disclosed herein is a ready-to-use liquid, injectable formulation comprising lidocaine and epinephrine. Also disclosed herein is a process for preparing a ready-to-use liquid formulation comprising lidocaine and epinephrine, as well as methods for using the ready-to-use liquid formulation.

Abstract: The invention relates to an aqueous pharmaceutical composition comprising: a) bilastine or a pharmaceutically acceptable salt or solvate thereof, b) mometasone, or a pharmaceutically acceptable derivative thereof, c) a suspending agent, and d) 2-hydroxypropyl-?-cyclodextrin; wherein the pH of the aqueous pharmaceutical composition is between 3.5 and 5.5, and wherein the content of 2-hydroxypropyl-?-cyclodextrin is less than 8.5% by weight. The invention also relates to said compositions for use in the treatment and/or prevention of a disorder or disease susceptible to amelioration by antagonism of H1 histamine receptor and/or of a corticosteroid-responsive disease through nasal administration. The invention also relates to a process for preparing the aqueous pharmaceutical composition above mentioned.

Abstract: A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.

Abstract: Non-invasive Ocular Drug Delivery Insert Technology. The invention concerns an ocular insert which is a new biocompatible polymer-based controlled drug delivery system (CDDS) applicable to a variety of drugs and other compounds for the treatment of different ocular pathologies. This ocular insert allows releasing of at least one drug under suitable concentration levels during suitable periods of time. The device may be inserted in the lower or upper fornix conjunctiva, in a non-invasive way, meaning that the patient will be able to place the device himself, without intervention of medical specialized staff. The insert of the invention will release the drug in such a controlled rate that will allow the drug release up to 300 days by either a “Fickian” or a linear profile according to the intend purpose or pathology.

Abstract: Disclosed is a dry powder oral formulation that includes an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation. Also disclosed are an excipient composition in absence of an API and methods of making and using the formulations and compositions. Also disclosed is a chewable, swallowable, and/or orally disintegrating tablet comprising an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation.

Abstract: The presently disclosed subject matter describes the use of fluorinated elastomer-based materials, in particular perfluoropolyether (PFPE)-based materials, in high-resolution soft or imprint lithographic applications, such as micro- and nanoscale replica molding, and the first nano-contact molding of organic materials to generate high fidelity features using an elastomeric mold. Accordingly, the presently disclosed subject matter describes a method for producing free-standing, isolated nanostructures of any shape using soft or imprint lithography technique.

Abstract: The present invention relates to a process for the production of a homogenous mixture of two or more branched chain keto acids wherein in a first step, two or more free keto acids are mixed, and in a second step, the mixed keto acids are co-crystallized with one or more alkaline earth metal salts, and foodstuff, food supplement or pharmaceutical products containing a mixture of branched-chain keto acids for supporting muscle structure, increasing muscle performance and improving general wellbeing with simultaneous relief of nitrogen detoxification metabolism by reduced nitrogen supply compared to the intake of the corresponding amino acids and an improved nitrogen metabolism in the body.

Abstract: A method of preparing a pharmaceutical product comprises the steps of (a) providing a neat active pharmaceutical ingredient (API) complying with at least five of the following parameters determined by using a FT4 powder rheometer: (i) specific basic flow energy of at most 60 mJ/g; (ii) stability index of 0.75 to 1.25; (iii) specific energy of at most 10 mJ/g; (iv) major principle stress at 15 kPa of at most 40; (v) flow function at 15 kPa of at least 1.3; (vi) consolidated bulk density at 15 kPa of at least 0.26 g/mL; (vii) compressibility of at most 47%; and (viii) wall friction angle of at most 40°; (b) dispensing the neat API of step (a) into a bottom part of a pharmaceutical carrier using a vacuum assisted metering and filling device; and (c) encapsulating the bottom part, thereby producing a pharmaceutical product.

Abstract: A method for preparing a water-soluble curcumin mixture with high bioavailability includes the following steps: A) dissolving curcumin, vitamin C and ascorbyl palmitate in an ethanol aqueous solution, evaporating ethanol under reduced pressure, and vacuum drying to obtain a curcumin-vitamin C-ascorbyl palmitate co-crystal; B) high-speed emulsifying the curcumin-vitamin C-ascorbyl palmitate co-crystal and a wall material colloidal solution under vacuum, sequentially conducting a two-stage wet grinding, a homogenization and a potential adjustment to obtain an emulsified body; and C) subjecting the emulsified body to microencapsulation with a wall material twice and drying to obtain the water-soluble curcumin.

Abstract: Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.

Abstract: The present invention relates to a method for improving lactic acid bacteria in survival rate, storage stability, resistance to acid or bile, and adherence to intestinal epithelial cells by coating the surface of lactic acid bacteria with silk fibroin, and a lactic acid bacteria composition prepared therethrough. Conventional techniques construct only a physical protective barrier outside a lactic acid bacteria body by multi-stage coating and thus retain the limitation of being unable to identify an effect on the coherence of lactic acid bacteria to intestinal epithelial cells upon the uptake of the lactic acid bacteria. In contrast, the present invention provides a method in which lactic acid bacteria is coated with silk fibroin extracted from cocoons, whereby the lactic acid bacteria is improved in stability under a storage and distribution condition as well as having remarkably increased stability and intestinal adherence particularly under an intestinal environment.

Abstract: Methods for intravesical administration of a therapeutic agent including application of a photoactive nanogel to the mucosal surfaces of the bladder and/or intravesical application of cell-penetrating peptides. Photoactive nanogels may be aggregated by exposure to ultraviolet light, either in vitro or in vivo, to provide controlled or extended release of a therapeutic agent, such as an antibiotic.

Abstract: The present invention relates to anti-inflammatory drug formulation. Especially, this invention relates to corticosteroid prodrug nanoparticle. In a first aspect, this invention relates to a nanoparticle comprising a therapeutic agent and a surface coating material. The invention also relates to a process of manufacturing at least one nanoparticle of invention. The invention also relates to pharmaceutical composition and pharmaceutical kits.

Abstract: The present Invention relates to the use of choline butyrate or butyrylcholine in food and in particular in the treatment of Intestinal disorders and in the stimulation of the brain development. Furthermore, the invention provides for a food supplement and a pharmaceutical composition comprising choline butyrate or butyrylcholine, The invention also relates to an animal feed comprising choline butyrate or butyrylcholine or said food supplement.

Abstract: A method for modulating metabolism is provided which includes the step of providing a consumable composition including an extract containing a compound of Formula I to a subject in need thereof thereby modulating the subject's metabolism and addressing the underlying pathogenesis of metabolic disorders, such as nonalcoholic fatty liver disease, nonalcoholic steatohepatitis and type II diabetes mellitus.

Abstract: The present disclosure relates to pharmaceutical compositions of tranexamic acid and methods of using the compositions. The pharmaceutical compositions of the present disclosure are stable and suitable for topical application.

Abstract: Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating disease. The compositions of such embodiments include dicarboxylic acid compounds containing electron withdrawing groups, alkyl esters of dicarboxylic acids containing electron withdrawing groups, or compounds of Formulae I to X. The methods of various embodiments include administering an effective amount of any of these pharmaceutical compositions to a patient in need of treatment.

Abstract: Compositions containing one or more kinds of essential amino acids other than leucine and not less than 35 mol % of leucine, relative to the total content of essential amino acids, are useful for preventing or improving dementia or a depressive state, in particular, a depressive state caused by stress, have high safety, and can be continuously ingested or administered.

Abstract: Disclosed herein is a nutritional supplement containing creatine, including compositions, formulations, and combinations of ingredients in the creatine nutritional supplement, as well as processes for manufacturing these supplements. The disclosed nutritional supplement can include creatine, a gelling agent such as pectin or gelatin, an oligosaccharide, a disaccharide, and water.

Abstract: The application describes creatine or its derivatives, compositions comprising the same, and uses thereof for topical or systemic administration to treat pain, itch, or eczema, or inflammation associated with a cosmetic or medical condition, disorder or disease in a human subject, wherein the inflammation causes the pain, itch, or eczema. In addition, the application describes clinical use of these compounds and compositions which can reduce or eliminate erythema, edema and tissue distortions associated with inflammation.